Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.
View Top Employees from Celyad OncologyWebsite | http://www.celyad.com |
Ticker | CYAD |
Revenue | $8000 |
Funding | $140.1 million |
Employees | 81 (67 on RocketReach) |
Founded | 2007 |
Address | Rue Edouard Belin 12, Mont-Saint-Guibert, Wallonia 1435, BE |
Phone | (321) 039-4100 |
Fax | (321) 039-4141 |
Technologies |
JavaScript,
HTML,
PHP
+26 more
(view full list)
|
Industry | Biotechnology, Drug Manufacturing & Research, Immuno-Oncology, Pharmaceuticals, Science and Engineering, Other Pharmaceuticals and Biotechnology, Cancer, Healthcare, Medical Device, Immnotherapy, Health Care, Natural Killer Receptors, Therapeutics |
Web Rank | 2 Million |
Keywords | Celyad, Celyad Belgium, Celyad Investors, Celyad Founder, Celyad Sec Filings |
Competitors | CARsgen Therapeutics, Immatics, Legend Biotech, SQZ Biotechnologies, Tessa Therapeutics Ltd |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies |
Looking for a particular Celyad Oncology employee's phone or email?
The Celyad Oncology annual revenue was $8000 in 2023.
Georges Rawadi is the CEO of Celyad Oncology.
67 people are employed at Celyad Oncology.
Celyad Oncology is based in Mont-Saint-Guibert, Wallonia.
The NAICS codes for Celyad Oncology are [3254, 32, 32541, 325].
The SIC codes for Celyad Oncology are [283, 28].